Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase. [electronic resource]
Producer: 19950817Description: 365-73 p. digitalISSN:- 0735-1097
- Adult
- Aged
- Amino Acid Sequence
- Confounding Factors, Epidemiologic
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Enzyme Precursors -- therapeutic use
- Female
- Fibrinolytic Agents -- therapeutic use
- Heparin -- administration & dosage
- Humans
- Injections, Intravenous
- Male
- Middle Aged
- Molecular Sequence Data
- Myocardial Infarction -- drug therapy
- Recombinant Proteins -- therapeutic use
- Thrombolytic Therapy
- Time Factors
- Treatment Outcome
- Urokinase-Type Plasminogen Activator -- therapeutic use
- Vascular Patency -- drug effects
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.